Pharmabcine Inc.

Korea Research Institute of Bioscience and Biotechnology

Weon Sup Lee

Sang Soon Byun

Sang Ryeol Shim

Hyuk Jin Lee

Jae Bong Yoon

Jin San Yoo

Seon Young Lee

Sung Woo Kim

Do Yun Kim

Jin-San Yoo

Eun Hee Lee

Jong Geun Jeong

Nam Ye Kim

Seon Hwan Oh

Miju Park

Jinsang Yoo

Youngae Lee

Young Ae Lee

Sung-Woo Kim

Sang Hoon Lee

In Sook Park

Joong Kyu Kim

Jin Sook Lee

Jin Sang Yoo

Keunhee Oh

Do-yun Kim

Eun Jin Lee

Mi Ju Park

Jinhee Choi

Yeun Ju Kim

Kyung Hee Nahm

Ju Ryung Nam

Bo Young Jeong

Sungho Ahn

Young Woo Park

Chae Ok Yun

Semi Kim

Dong Heon Lee

Do-Yun Kim

Kwi Hwa Kim

Young Guen Kwon

Jae Won Jeon

Sang Seok Koh

Bo Jeong Pyun

Jin Hee Choi

Shin Ae Yi

Hyun Sook Jang

Hyuk Joon Lee

Ju Ryoung Nam

Jung Min Ha

Ji Hye Jeong

Yeon Ju Kim

Mi Hee Park

Mi Ae Jeon

Kyoung Hee Nahm

Joon Chul Lee

Boyoung Jeong

Jeong Eun Kang

Geun Bae Rha

Dong Sup Lee

Too Hyon Cho

Nahm Ju Kim

Hyeon Mi Yoo

Sam Sook Sul

Disclosed are an anti-PD-L1 antibody or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector including the nucleic acid, a cell transformed with the vector, a method for producing the antibody or an antigen-binding fragment thereof, a pharmaceutical composition for preventing or treating cancer containing the same, and a composition for co-administration with an antibody other than an antibody binding to PD-L1, containing the same.

Anti-PD-L1 antibody and use thereof

The present invention relates to an anti-VISTA antibody or an antigen binding fragment thereof, a nucleic acid coding for the same, a vector carrying the nucleic acid, a cell transformed with the vector, a method for preparing the antibody or an antigen binding fragment thereof, a composition for prevention or treatment of autoimmune disease, comprising the same antibody, and a composition for concurrent administration in combination with a PD-1 antibody or PD-L1 antibody.

Anti-VISTA antibody and use thereof

The present disclosure relates to an antibody specifically binding to epidermal growth factor receptor variant III (EGFRvIII), to nucleic acid coding the antibody, to a vector comprising the nucleic acid, to a host cell, to a preparation method of the antibody, and to a pharmaceutical composition comprising the antibody as an active ingredient for treating a cancer or a tumor.

EGFRvIII antibody and composition comprising same

The present invention relates to a novel form of a dual-target antibody targeting VEGFR-2 and DLL4, a gene encoding the same, a recombinant expression vector including the gene, host cells transformed with the recombinant expression vector, a method of producing the dual-target antibody using the host cells, a pharmaceutical composition comprising the dual-target antibody.

Dual-target antibody targeting VEGFR-2 and DLL4 and pharmaceutical composition including same

The present invention relates to: a dual targeting antibody of a novel form having a water-soluble ligand fused to the N-terminus of a heavy chain or light chain of an antibody; a DNA encoding the dual targeting antibody; a recombinant expression vector containing the DNA; a host cell which is transformed with the recombinant expression vector; a method for preparing the dual targeting antibody by culturing the host cell; and a pharmaceutical composition including the dual targeting antibody.

Dual targeting antibody of novel form, and use thereof

Provided are an antibody specifically bound to c-Met (c-Met-specific antibody) or fragments thereof, and more specifically, a fully human antibody having high affinity and specificity to c-Met isolated from human Fv(ScFv) phage library, a polynucleotide encoding the antibody, a recombinant vector containing the polynucleotide, a cell transformed with the recombinant vector, and a method of producing the c-Met-specific antibody by culturing the cell, wherein the c-Met-specific antibody may effectively control activity of c-Met in vivo.

Human antibody specific to c-Met and preparation method thereof

Dual-target antibody targeting VEGFR-2 and DLL4, and pharmaceutical composition including same

Growing community of inventors

Daejeon, South Korea

Weon Sup Lee